Recordati, based in Milan, Italy, is an international pharmaceutical group that provides treatments across specialty and primary care, and rare diseases, including PA. Through this agreement, Moderna will continue to lead the clinical development of mRNA-3927 through approval and Recordati will lead commercialization. "We are proud to partner with Recordati in a joint mission to improve the lives of people living with propionic acidemia," said Stéphane Bancel, Chief Executive Officer of Moderna. "Recordati brings deep rare disease commercial expertise and an established global commercial infrastructure in propionic acidemia that will help us accelerate the benefit of mRNA-3927 upon approval." These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.